PRX005 is a monoclonal antibody therapeutic targeting the microtubule-binding region (MTBR) of tau, developed by Prothena Biosciences in partnership with Bristol Myers Squibb for the treatment of Alzheimer's disease and other tauopathies. This represents a next-generation approach to tau immunotherapy that addresses the limitations of earlier anti-tau antibody programs.
PRX005 is an IgG1 monoclonal antibody that specifically targets the MTBR of tau protein, particularly the region involved in tau-tau aggregation and fibril formation. This approach distinguishes PRX005 from earlier-generation anti-tau antibodies that targeted N-terminal epitopes, which failed to demonstrate clinical efficacy in Phase II trials.
The development of PRX005 reflects a major paradigm shift in tau immunotherapy strategy:
- First-generation anti-tau antibodies targeted the N-terminal region of tau
- These failed in clinical trials (gosuranemab, tilavonemab, semorinemab)
- Second-generation approaches target the MTBR, which is the aggregation "seed" region
¶ Tau Biology and Pathological Relevance
Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17q21. It exists as six isoforms in the adult human brain, ranging from 352 to 441 amino acids. The protein comprises:
- N-terminal region (1-150 aa): Projection domain, projects away from microtubules
- Proline-rich region (151-244 aa): Multiple phosphorylation sites
- Microtubule-binding region (244-368 aa): 3-4 repeat sequences (R1-R4)
- C-terminal region (369-441 aa): Involved in aggregation
¶ MTBR Structure and Function
The microtubule-binding region (MTBR) consists of:
- Repeat 1 (R1): VQIVYK (306-378)
- **Repeat 2 (R2): VQIINK (274-280)
- **Repeat 3 (R3): VQIVYK (306-378)
- **Repeat 4 (R4): VQIVYK (336-378)
The core hexapeptide motifs VQIVYK and VQIINK form the β-sheet structure essential for tau filament formation. The MTBR is the " Achilles heel" of tau aggregation.
In Alzheimer's disease and tauopathies, tau undergoes:
- Hyperphosphorylation: Reduces microtubule binding
- Oligomerization: Forms toxic soluble oligomers
- Fibrillization: Forms paired helical filaments (PHFs) and straight filaments (SFs)
- Aggregation: Forms neurofibrillary tangles (NFTs)
PRX005 binds to the MTBR region of tau, which contains the core aggregation-prone sequence (Q244-K280, V306-K378) responsible for fibril formation. By targeting this region, PRX005 aims to:
- Intercept tau aggregation at its nucleation site
- Clear both intracellular and extracellular pathological tau
- Potentially reduce tau seeding and propagation
- Prevent cell-to-cell transmission of pathology
- MTBR binding: PRX005 binds with high affinity to pathological tau species containing the MTBR
- Fc-mediated clearance: IgG1 subclass enables efficient microglial uptake via Fc receptors
- Intracellular engagement: May engage TRIM21 for intracellular tau clearance
- Seed neutralization: Binding may neutralize tau seeds that propagate pathology
- Extracellular sink: May reduce extracellular tau that spreads between neurons
The rationale for MTBR targeting is based on several key observations:
- MTBR contains the core aggregation domain (VQIVYK hexapeptide)
- Pathological tau fragments enriched in MTBR are highly aggregation-prone
- N-terminal antibodies fail because they don't intercept the aggregation machinery
- MTBR antibodies can potentially enter cells and target intracellular tau
| Trial ID |
Phase |
Status |
Population |
| NCT05420546 |
Phase I |
Recruiting |
Early AD |
| NCT05535756 |
Phase I |
Completed |
Healthy volunteers |
Phase I studies evaluate:
- Safety and tolerability
- Pharmacokinetics
- Target engagement (CSF tau reduction)
- Immunogenicity
Based on mechanism and preclinical data:
- Dose-dependent reduction in CSF tau species
- Potential slowing of cognitive decline
- Generally well-tolerated safety profile
¶ Anti-Tau Antibody Landscape
| Drug |
Company |
Target Epitope |
IgG Type |
Phase |
Key Outcome |
| PRX005 |
Prothena/BMS |
MTBR |
IgG1 |
Phase I |
Ongoing |
| E2814 |
Eisai |
MTBR (HVPGG) |
IgG1 |
Phase III |
DIAN-TU trial |
| Bepranemab |
UCB |
aa 235-250 |
IgG4 |
Phase II |
Mixed results |
| Semorinemab |
Roche |
N-terminus |
IgG4 |
Phase II |
Failed TAURIEL |
| Gosuranemab |
Biogen |
N-terminus |
IgG1 |
Phase II |
Failed |
| Tilavonemab |
Lilly |
N-terminus |
IgG1 |
Phase II |
Failed |
| Zagotenemab |
Lilly |
MC1 |
IgG1 |
Phase II |
Failed |
- Epitope selection: MTBR vs N-terminal
- IgG subclass: IgG1 (PRX005) vs IgG4 (bepranemab, semorinemab)
- Mechanism: Direct aggregation inhibition vs extracellular clearance
IgG1 advantages:
- Stronger Fc effector function
- Better microglial activation
- Enhanced intracellular clearance via TRIM21
- More potent tau reduction in preclinical models
IgG4 limitations:
- Weaker Fc effector function
- Reduced clearance capability
- Less effective in clinical trials to date
- PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
- Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
- Neutralizes tau seeding activity in biosensor cells
- Does not bind to normal tau in mouse brain
- Reduces insoluble tau in tau transgenic mouse models
- Improves behavioral deficits in tauopathy models
- Does not affect normal microtubule function
- Good brain penetration in non-human primates
Prothena is a late-stage clinical biotechnology company headquartered in San Francisco, California. The company focuses on:
- Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS)
- Amyloid-related disorders (AL amyloidosis)
- Antibody discovery and development
Key Tau Programs:
- PRX005 (MTBR antibody, partnered with BMS)
- PRX012 (anti-Aβ antibody)
- PRX002 (α-synuclein antibody)
BMS acquired rights to PRX005 through a 2023 partnership agreement:
- BMS received exclusive worldwide rights
- Prothena retained certain co-development options
- Total deal value: $2.2 billion including upfront and milestones
- Disease modification: Targets underlying tau pathology
- Complementary to anti-amyloid: Can be combined with lecanemab
- Broad applicability: Potential for AD, PSP, CBD, FTD
- Novel mechanism: Addresses failed N-terminal approach
¶ Challenges and Limitations
- Intracellular tau: Antibodies have limited access
- BBB penetration: Requires sufficient brain exposure
- Safety monitoring: ARIA risk (like anti-amyloid antibodies)
- Combination complexity: Regulatory pathway for combinations
Ideal candidates for PRX005 may include:
- Early-stage Alzheimer's disease (MCI or mild dementia)
- Elevated tau on PET or CSF
- Amnestic phenotype
- Amyloid-positive status
- Infusion-related reactions
- Headache
- Amyloid-related imaging abnormalities (ARIA) - theoretical risk
- MRI before and during treatment
- Periodic cognitive assessment
- CSF biomarkers (optional)
Based on current development:
- Phase II: Dose-finding in early AD
- Phase III: Pivotal trials in early AD
- Potential accelerated approval with biomarker endpoint
Rationale for combination:
- Anti-amyloid + anti-tau: Complementary mechanisms
- PRX005 + lecanemab: Both targeting pathological proteins
- Triple therapy: Add anti-neuroinflammatory
¶ Competitive Landscape
The tau immunotherapy field has seen multiple failures, creating both challenge and opportunity:
Failed approaches:
- N-terminal antibodies (gosuranemab, tilavonemab, semorinemab)
- Failed to meet primary endpoints in Phase II
Promising approaches:
- MTBR antibodies (E2814, PRX005, bepranemab)
- ASOs (BIIB080 showing tau reduction)
- Small molecules (OGA inhibitors)
PRX005 is currently in Phase 2 development for Alzheimer's disease:
| Trial ID |
Phase |
Status |
Population |
| NCT06268886 |
Phase 2 |
Recruiting |
Early AD (CDR 0.5 or 1) |
| NCT05420546 |
Phase 1 |
Completed |
Early AD |
| NCT05535756 |
Phase 1 |
Completed |
Healthy volunteers |
Top-line Phase 1 results announced January 31, 2023 showed:
- CNS Penetration: Achieved 0.2% of plasma levels in CNS (meaningful exposure)
- Safety: All doses were safe and well-tolerated with no serious adverse events
- Dose-Proportional PK: Linear pharmacokinetics across dose levels tested
- Immunogenicity: No significant anti-drug antibody formation
The Phase 2 trial (NCT06268886) represents a significant advancement:
- Enrollment: 475 participants with early AD (CDR 0.5 or 1)
- Duration: 72-week treatment course
- Dosing: Two dose levels vs placebo
- Primary Endpoint: CDR-SB change from baseline
- Sites: 199 sites across North America, Australia, Asia, and Europe
- Expected Completion: 2027
BMS acquired rights to PRX005 through a 2023 partnership agreement with Prothena:
- BMS received exclusive worldwide rights (July 2023)
- Prothena retained certain co-development options
- Total deal value: $2.2 billion including upfront and milestones
- BMS rebranded the asset as BMS-986446
The rationale for MTBR targeting is based on several key observations:
- Core of Fibrils: The MTBR forms the core of tau fibrils in Alzheimer's disease
- Template Function: This region templates the conversion of normal tau to pathological forms
- Conserved Epitope: The HVPGGG sequence is highly conserved and present in all tau isoforms
- Intracellular Access: MTBR antibodies can potentially enter cells and target intracellular tau
Recent cryo-EM studies have revealed the atomic structure of tau filaments:
- MTBR forms the core of both PHFs and straight filaments
- The VQIVYK hexapeptide forms β-sheet rich structures
- Pathological tau adopts distinct conformations in different diseases
- Understanding these structures informs antibody design
A key mechanism for MTBR-targeting antibodies is the TRIM21 pathway:
- Intracellular Antibody Entry: Tau-specific antibodies can enter neurons via Fc receptors
- TRIM21 Binding: Antibody-tau complexes are recognized by TRIM21, an E3 ubiquitin ligase
- Proteasomal Degradation: TRIM21 polyubiquitinates the complex for proteasome-mediated clearance
- Clinical Benefit: This intracellular mechanism may explain superior efficacy vs N-terminal antibodies
The choice of IgG1 subclass provides significant advantages:
IgG1 advantages:
- Stronger Fc effector function (ADCC, CDC)
- Better microglial activation via FcγR
- Enhanced intracellular clearance via TRIM21
- More potent tau reduction in preclinical models
IgG4 limitations:
- Weaker Fc effector function
- Reduced clearance capability
- Less effective in clinical trials to date
- PRX005 binds to recombinant human tau with high affinity (KD < 100 pM)
- Recognizes aggregated tau forms (PHFs, SFs) better than monomeric tau
- Neutralizes tau seeding activity in biosensor cells
- Does not bind to normal tau in mouse brain
- Reduces insoluble tau in tau transgenic mouse models
- Improves behavioral deficits in tauopathy models
- Does not affect normal microtubule function
- Good brain penetration in non-human primates
Key translation findings from preclinical to clinical:
- CNS penetration at 0.2% of plasma levels achieved in humans
- Dose-proportional PK supports monthly dosing
- Safety profile supports advancement to Phase 2
Prothena is a late-stage clinical biotechnology company headquartered in San Francisco, California. The company focuses on:
- Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS)
- Amyloid-related disorders (AL amyloidosis)
- Antibody discovery and development
Key Tau Programs:
- PRX005 (MTBR antibody, partnered with BMS)
- PRX012 (anti-Aβ antibody)
- PRX002 (α-synuclein antibody)
BMS acquired rights to PRX005 through a 2023 partnership agreement:
- BMS received exclusive worldwide rights
- Prothena retained certain co-development options
- Total deal value: $2.2 billion including upfront and milestones
- BMS has rebranded PRX005 as BMS-986446
Prothena maintains a robust pipeline targeting neurodegenerative diseases:
| Asset |
Target |
Stage |
Partner |
| PRX005 (BMS-986446) |
Tau MTBR |
Phase 2 |
BMS |
| PRX012 |
Aβ |
Phase 1 |
— |
| PRX002 |
α-synuclein |
Preclinical |
Roche |
- Disease modification: Targets underlying tau pathology
- Complementary to anti-amyloid: Can be combined with lecanemab
- Broad applicability: Potential for AD, PSP, CBD, FTD
- Novel mechanism: Addresses failed N-terminal approach
¶ Challenges and Limitations
- Intracellular tau: Antibodies have limited access
- BBB penetration: Requires sufficient brain exposure
- Safety monitoring: ARIA risk (like anti-amyloid antibodies)
- Combination complexity: Regulatory pathway for combinations
Ideal candidates for PRX005 may include:
- Early-stage Alzheimer's disease (MCI or mild dementia)
- Elevated tau on PET or CSF
- Amnestic phenotype
- Amyloid-positive status
- Infusion-related reactions
- Headache
- Amyloid-related imaging abnormalities (ARIA) - theoretical risk
- MRI before and during treatment
- Periodic cognitive assessment
- CSF biomarkers (optional)
Based on current development:
- Phase II: Dose-finding in early AD (2024-2027)
- Phase III: Pivotal trials in early AD (2027-2029)
- Potential accelerated approval with biomarker endpoint
Rationale for combination:
- Anti-amyloid + anti-tau: Complementary mechanisms
- PRX005 + lecanemab: Both targeting pathological proteins
- Triple therapy: Add anti-neuroinflammatory
BMS's neuroscience focus:
- Expansion into Alzheimer's disease via partnership with Prothena
- Leveraging immunology expertise from oncology
- Strategic priority on disease-modifying therapies
¶ Pharmacokinetics and Pharmacodynamics
The pharmacokinetic profile of PRX005 has been characterized in clinical studies:
- Half-life: Approximately 21-28 days, consistent with typical IgG1 antibodies
- Volume of distribution: Approximately 3-4 L, indicating distribution primarily in plasma
- Clearance: Low clearance supporting q4w or q8w dosing
- CNS penetration: 0.2% of plasma levels - meaningful for target engagement
Phase 1 data demonstrated dose-proportional pharmacokinetics across the dose range tested:
- Linear exposure from low to high doses
- No accumulation with repeated dosing
- Steady state achieved by approximately 4-5 half-lives
The pharmacodynamic effects include:
- Tau PET Reduction: Expected to reduce tau accumulation (similar to other MTBR antibodies)
- CSF Biomarker Modulation: Dose-dependent reduction in p-tau species expected
- Plasma Tau Effects: Modulation of peripheral tau species
- Duration of Effect: Sustained effects observed throughout treatment period
Population PK/PD modeling has informed:
- Efficacy: Higher exposure associated with greater target engagement
- Safety: No clear exposure-safety relationship for AEs
- Dosing: Supports q4w or q8w dosing intervals
Based on clinical trial data, the PRX005 dosing regimen is:
- Route: Intravenous infusion
- Dose: Multiple dose levels tested in Phase 1
- Frequency: Every 4 weeks (q4w)
- Infusion Time: Approximately 1-2 hours
- Premedication: Not typically required
The doses selected for Phase 2 were based on:
- Target Engagement: Demonstrated CSF target engagement in Phase 1
- Safety Margin: Favorable safety profile across dose levels
- Practical Considerations: Balance of efficacy and manufacturing costs
In clinical practice, PRX005 would be administered:
- IV infusion in a clinical setting with monitoring
- Baseline assessments including MRI, tau PET, CSF sampling
- Periodic monitoring for safety and biomarker responses
- Long-term treatment expected for disease modification
- Age 50-85 years
- Clinical diagnosis of MCI due to AD or mild AD dementia
- Confirmed amyloid positivity (PET or CSF)
- Tau PET positive
- MMSE score ≥ 20
- Stable on permitted medications
- Other neurodegenerative diseases (e.g., Parkinson's disease)
- Significant psychiatric comorbidity
- History of stroke or TIA within 2 years
- Contraindications for MRI
- Current participation in other clinical trials
PRX005 is currently in Phase 2 development with BMS as the sponsor:
- FDA: No Fast Track or Breakthrough designation (as of 2024)
- EMA: No PRIME designation (as of 2024)
- Development: Advancing through BMS partnership
Given the current data, potential registration pathways include:
- Accelerated Approval: Based on tau-PET biomarker effects
- Traditional Approval: Based on clinical endpoints in Phase 3
- Combination Approval: With anti-amyloid therapies
- Clinical Endpoint: Demonstrating clinically meaningful benefit
- Patient Selection: Identifying biomarker-defined responders
- Comparator: No head-to-head comparison with other anti-tau antibodies
¶ Position in Tau Immunotherapy Landscape
PRX005 occupies a leading position among anti-tau antibodies in development:
| Feature |
PRX005 |
Competitors |
| Target |
MTBR |
Various |
| Phase |
Phase 2 |
Phase 2-3 |
| Company |
BMS/Prothena |
Eisai, UCB |
| Combination |
Monotherapy |
Some with lecanemab |
- MTBR Targeting: Direct targeting of aggregation-prone region
- IgG1 Fc: Efficient microglial clearance
- BMS Resources: Leverages BMS development infrastructure
- Biomarker Validation: Expected strong CSF biomarker data
- BMS Partnership: Strategic priority for BMS
¶ Challenges and Risks
- Complexity of tau biology: Multiple pathological species
- Clinical translation: Biomarker success not yet translated to cognitive benefit
- Competition: Other MTBR antibodies in development
- Regulatory pathway: Novel endpoints for disease modification
- 2025-2026: Complete Phase 2 enrollment
- 2027: Phase 2 data readout
- 2028: Potential Phase 3 initiation
- Early Alzheimer's Disease: Primary indication
- Mild Cognitive Impairment: Pre-dementia stages
- Other Tauopathies: Potential for PSP, CBD extension
Future development may include:
- Subcutaneous formulation (improved convenience)
- Higher-affinity variants
- Bispecific antibodies (tau + amyloid)
¶ Comparison with E2814 and Bepranemab
| Feature |
PRX005 |
E2814 |
Bepranemab |
| Company |
BMS/Prothena |
Eisai |
UCB |
| Target |
MTBR |
MTBR (HVPGG) |
Central region |
| IgG Type |
IgG1 |
IgG1 |
IgG4 |
| Phase |
Phase 2 |
Phase 3 |
Phase 2 |
| CNS Penetration |
0.2% plasma |
~0.1% plasma |
~0.1% plasma |
PRX005 occupies a unique position:
- Only Phase 2 MTBR antibody in BMS portfolio
- Strong BMS partnership provides resources
- Differentiated from E2814 (Eisai) and bepranemab (UCB)
- BMS-986446 branding suggests integration into BMS pipeline